Profil
Paul Sekhri is the founder of Aditum Bio Management Co. LLC.
He currently holds a position as Director at Aditum Bio Fund 1 LP.
Postes actifs de Paul Sekhri
| Sociétés | Poste | Début |
|---|---|---|
Aditum Bio Fund 1 LP
 Aditum Bio Fund 1 LP Investment ManagersFinance Aditum Bio Fund 1 LP specializes in acquiring and developing pharmaceutical assets. The company is headquartered in San Mateo, CA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Paul Sekhri
| Sociétés | Poste | Fin |
|---|---|---|
Aditum Bio Management Co. LLC
 Aditum Bio Management Co. LLC Investment ManagersFinance Aditum Bio Management Co. LLC is a biotech venture capital company based in Oakland, CA. Aditum Bio is committed to improving public health by accelerating research and development in disease areas with both large and more targeted patient populations. The private company focuses on basic mechanisms of disease, in-license promising drug candidates, and spin-out individual companies dedicated to bringing each candidate through phase II clinical trials. In partnership with Trialspark, Aditum Bio uses data, software, and technology to help bring innovative medicines through the clinical trial phase more quickly and with lower costs than traditional pharmaceutical companies. The company was founded by Paul Sekhri, Joseph Jimenez, and Mark Fishman. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Aditum Bio Fund 1 LP
Aditum Bio Fund 1 LP Investment ManagersFinance Aditum Bio Fund 1 LP specializes in acquiring and developing pharmaceutical assets. The company is headquartered in San Mateo, CA. | Finance |
Aditum Bio Management Co. LLC
Aditum Bio Management Co. LLC Investment ManagersFinance Aditum Bio Management Co. LLC is a biotech venture capital company based in Oakland, CA. Aditum Bio is committed to improving public health by accelerating research and development in disease areas with both large and more targeted patient populations. The private company focuses on basic mechanisms of disease, in-license promising drug candidates, and spin-out individual companies dedicated to bringing each candidate through phase II clinical trials. In partnership with Trialspark, Aditum Bio uses data, software, and technology to help bring innovative medicines through the clinical trial phase more quickly and with lower costs than traditional pharmaceutical companies. The company was founded by Paul Sekhri, Joseph Jimenez, and Mark Fishman. | Finance |
